Trials / Sponsors / Taris Biomedical LLC
Taris Biomedical LLC
Industry · 5 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Terminated | Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer Bladder Cancer TNM Staging Primary Tumor (T) T2, Bladder Cancer TNM Staging Primary Tumor (T) T2A, Bladder Cancer TNM Staging Primary Tumor (T) T2B | Phase 1 | 2019-01-02 |
| Completed | Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spina Neurogenic Detrusor Overactivity | Phase 1 | 2017-04-24 |
| Completed | Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder Idiopathic Overactive Bladder With Urinary Incontinence | Phase 1 | 2017-04-04 |
| Completed | Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer Urinary Bladder Cancer | Phase 1 | 2016-05-31 |
| Completed | Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer Urinary Bladder Cancer | Phase 1 | 2016-01-01 |